Minnesota is currently home to 2105 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
NCT06482905
Recruiting
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: High-grade Glioma, WHO Grade Ⅳ Glioma
Register for Updates
Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma
NCT05918185
Recruiting
This study evaluates the association between a comprehensive geriatric assessment and laboratory biomarkers with the side effects of chemotherapy in older patients with multiple myeloma (MM). The comprehensive geriatric assessment is a tool that can help to determine how fit a patient is. It is composed of a series of questions and tests designed for older people to evaluate their physical function, mental status, mental health, nutritional status, social support, level of social activity, and t... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/08/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Plasma Cell Myeloma
Register for Updates
ETHAN - ET for Male BC
NCT05501704
Recruiting
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Register for Updates
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
NCT04474223
Recruiting
Fetal complete (i.e., third degree, 3°) atrioventricular block (AVB), identified in the 2nd trimester of pregnancy in an otherwise normally developing heart, is almost universally associated with maternal anti-Ro autoantibodies and results in death in a fifth of cases. To date treatment of 3° AVB has been ineffective in restoring normal rhythm (NR) which may be because current surveillance is limited to once- weekly fetal echocardiograms. It is hypothesized that there may be a vital transition p... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Children's Hospital of Minnesota, Minneapolis, Minnesota
Conditions: AVB - Atrioventricular Block, Fetal AVB
Register for Updates
The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry
NCT01429727
Recruiting
The primary goal of this project is to describe the clinical and physiologic characteristics of Spontaneous Coronary Artery Dissections (SCAD) in order to increase awareness, understanding, treatment and prevention of a potentially fatal cardiovascular event. This study will be a retrospective and prospective review of medical course and current health of men and women with SCAD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/08/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Spontaneous Coronary Artery Dissection, SCAD
Register for Updates
A Study of Niacin Regulation
NCT06175403
Recruiting
Adults who gain most of their excess weight in the abdominal area typically do not respond to things that "turn off" fat cells the same way as lean people. The researchers are trying to understand why fat tissue responds differently in people with different body types.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/04/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Excessive Weight Gain
Register for Updates
A Study of the TactiFlex SE Catheter and Volt PFA Generator in Subjects With PAF:
NCT06676072
Recruiting
The objective of this clinical study is to demonstrate that ablation with the TactiFlex SE Ablation catheter, in conjunction with a compatible pulsed field ablation (PFA) and/or radio frequency (RF) generator, is safe and effective for the treatment of symptomatic, recurrent, drug refractory paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Atrial Fibrillation (AF), Atrial Arrhythmia, Paroxysmal AF, Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
Regional Lipolysis Insulin Regulation
NCT06392854
Recruiting
Adults who gain most of their excess weight in the abdominal area typically do not respond to insulin in the same way as lean adults. Researchers are trying to understand why fat tissue responds differently in people with different body types.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Obesity
Register for Updates
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
NCT06295770
Recruiting
The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Fibrillary Glomerulonephritis
Register for Updates
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
NCT05918692
Recruiting
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Acute Myeloid Leukemia
Register for Updates
Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture
NCT05116930
Recruiting
The purpose of this study is to evaluate Neostigmine and Glycopyrrolate to treat post-dural puncture headache (PDPH) to reduce the proportion of postpartum women with a PDPH requiring epidural blood patch (EBP) who developed a PDPH after accidental dural puncture.
Gender:
FEMALE
Ages:
Between 18 years and 54 years
Trial Updated:
04/03/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Post-Dural Puncture Headache
Register for Updates
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Riverwood Healthcare Center, Aitkin, Minnesota
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Register for Updates